Why Vosevi Costs $14,833.00 Per Claim
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) is used to treat hepatitis c. According to CMS Medicare Part D spending data, the program spent $178.0M on this drug, covering 2,800 beneficiaries across 12,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Sofosbuvir/Velpatasvir/Voxilaprevir or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Vosevi decreased by 28.6% year-over-year, likely due to generic competition reducing prices.
Price Breakdown
Drug Details
Frequently Asked Questions
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) costs an average of $14,833.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $63,571.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Vosevi averages $14,833.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Vosevi reflects in our Medicare Part D average of $14,833.00 per claim. Switching to generic Sofosbuvir/Velpatasvir/Voxilaprevir typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Vosevi, but coverage varies by formulary tier. Insurers typically prefer generic Sofosbuvir/Velpatasvir/Voxilaprevir (Tier 1, lowest copay) over brand-name Vosevi (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Sofosbuvir/Velpatasvir/Voxilaprevir is the single biggest cost reducer if your prescriber is open to it.
Brand-name Vosevi costs more than generic Sofosbuvir/Velpatasvir/Voxilaprevir primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.
Yes, a generic version of Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Sofosbuvir/Velpatasvir/Voxilaprevir.
Medicare Part D spent $178.0M on Vosevi, covering 2,800 beneficiaries across 12,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Sofosbuvir/Velpatasvir/Voxilaprevir, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.
The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.